MARINELLI, DANIELE
 Distribuzione geografica
Continente #
EU - Europa 718
NA - Nord America 535
AS - Asia 156
AF - Africa 9
SA - Sud America 3
Totale 1.421
Nazione #
US - Stati Uniti d'America 523
IT - Italia 329
SE - Svezia 276
SG - Singapore 109
IN - India 30
DE - Germania 29
FI - Finlandia 22
BG - Bulgaria 14
IE - Irlanda 11
CN - Cina 9
GB - Regno Unito 9
TG - Togo 8
CA - Canada 7
FR - Francia 4
MX - Messico 4
NL - Olanda 4
RO - Romania 4
ES - Italia 3
IR - Iran 3
UA - Ucraina 3
BE - Belgio 2
CZ - Repubblica Ceca 2
HK - Hong Kong 2
PH - Filippine 2
AL - Albania 1
AR - Argentina 1
AT - Austria 1
CH - Svizzera 1
CL - Cile 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
EE - Estonia 1
IL - Israele 1
PT - Portogallo 1
VA - Santa Sede (Città del Vaticano) 1
ZA - Sudafrica 1
Totale 1.421
Città #
Stockholm 174
Rome 141
Singapore 70
Chandler 65
Fairfield 65
Boardman 28
Ashburn 27
Princeton 22
Helsinki 20
Milan 20
San Paolo di Civitate 15
New York 14
Sacramento 14
Sofia 14
Seattle 13
Wilmington 13
Woodbridge 13
Cambridge 12
Millbury 12
Houston 11
Andover 10
San Diego 10
Boston 9
Bremen 9
Dublin 9
Lawrence 9
Naples 9
Ann Arbor 8
Lomé 8
Padova 8
Santa Clara 7
Florence 5
Toronto 5
Catania 4
Los Angeles 4
Norwalk 4
Turin 4
Dallas 3
Mannheim 3
Mexico City 3
Albignasego 2
Amsterdam 2
Arezzo 2
Boydton 2
Brescia 2
Brugherio 2
Brussels 2
Bühl 2
Calvanico 2
Carignano 2
Castelnuovo di Porto 2
Central 2
Des Moines 2
Formia 2
Frankfurt am Main 2
Genoa 2
Hangzhou 2
Lappeenranta 2
Magenta 2
Manchester 2
Messina 2
Miramar 2
Misterbianco 2
Montréal 2
Munich 2
Pomezia 2
Rapolla 2
Ravenna 2
Rosora 2
San Antonio 2
Silea 2
Vallefoglia 2
Varedo 2
Zhengzhou 2
Ancona 1
Arrecife 1
Azor 1
Barcelona 1
Beijing 1
Bentivoglio 1
Bern 1
Binghamton 1
Birmingham 1
Cheyenne 1
Corridonia 1
Düsseldorf 1
Edinburgh 1
Ercolano 1
Fano 1
Federal 1
Frosinone 1
Fuzhou 1
Groningen 1
Guayaquil 1
Guidonia Montecelio 1
Kashan 1
Leawood 1
Levallois-perret 1
Menlo Park 1
Montclair 1
Totale 988
Nome #
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial 184
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 61
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden 60
KEAP1 and TP53 frame genomic, evolutionary and immunological subtypes of lung adenocarcinoma with different sensitivity to immunotherapy 60
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 59
127P {RAS}, {RAF} and {NF}1 oncogenic mutations in {KRAS}-mutated lung adenocarcinoma 57
Neoadjuvant immune-checkpoint blockade in triple-negative breast cancer: current evidence and literature-based meta-analysis of randomized trials 54
Comparison of two blood-based genotyping tests to investigate the KRAS G12C mutation in patients with non-small-cell lung cancer at failure of first-line treatments 53
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes 51
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study 49
CDKN2A/B gene loss and MDM2 alteration as a potential molecular signature for hyperprogressive disease in advanced NSCLC: A next-generation-sequencing approach 49
Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives 48
3MO Oncogenic non-G12C {KRAS} mutations in {KRAS} G12C mutated lung adenocarcinomas in {TRACERx} and {GENIE}: A reservoir for intrinsic resistance to {KRAS} G12C inhibitors 48
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience 43
The potential role of genomic signature in stage II relapsed colorectal cancer (CRC) patients: a mono-institutional study 42
Analysis of molecular biomarkers in resected early-stage non-small cells lung cancer: a narrative review 38
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 38
Observational multicenter study on the prognostic relevance of coagulation activation in risk assessment and stratification in locally advanced breast cancer. Outline of the arias trial 37
Nodal upstaging evaluation after robotic-assisted lobectomy for early-stage non-small cell lung cancer compared to video-assisted thoracic surgery and thoracotomy: a retrospective single center analysis 36
Circulating hpv dna in the management of oropharyngeal and cervical cancers: current knowledge and future perspectives 35
Prospective assessment of targeted symptom management on supportive care in cancer: An observational cohort study 34
Comparative effects of Folfirinox and Gemcitabine/nab-paclitaxel as first and second line chemotherapy for metastatic pancreatic cancer: single choice or sequence 34
Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis 32
KEAP1-NFE2L2 Mutations in NSCLC: Increased Awareness Needed. Reply to “KEAP1-NFE2L2–Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis” 28
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study 27
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials 24
167P Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute 23
Burnout of health care providers during the covid-19 pandemic: Focus on medical oncologists 23
null 21
Prognostic relevance of neutrophil to lymphocyte ratio (Nlr) in luminal breast cancer: A retrospective analysis in the neoadjuvant setting 20
Neoadjuvant endocrine therapy in breast cancer. Current knowledge and future perspectives 20
86P {KRAS} G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma 19
TRF2 and VEGF-A: An unknown relationship with prognostic impact on survival of colorectal cancer patients 19
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study 18
Multicohort and cross-platform validation of a prognostic Wnt signature in colorectal cancer 16
56P The prognostic role of {KRAS} mutations in patients with early-stage lung adenocarcinoma after robotic lobectomy and systematic lymphadenectomy 15
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study 15
Immunotherapy-Based Combinations in First-Line Urothelial Cancer: A Systematic Review and Individual Patient Data (IPD) Meta-Analysis 14
Palliative sedation and time to death in home palliative care: retrospective analysis 13
KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma 12
Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis 11
Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease 7
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study 6
11P Reconstructing tumour evolution of single cells using both somatic mutations and copy-number alterations 6
Analysis of predictive factors of unforeseen nodal metastases in resected clinical stage I NSCLC 6
Systemic treatment of mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer-single versus double checkpoint inhibition 5
Abstract PR010: Linking proliferation rate to the evolution of single-cell primary and metastatic tumor clones 4
Training and telemedicine: the key to the palliative medicine specialist shortage? 4
Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy 1
Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience 1
Totale 1.580
Categoria #
all - tutte 7.888
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.888


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202019 0 0 0 0 0 0 0 9 2 7 0 1
2020/2021104 0 1 0 3 2 1 6 16 15 51 9 0
2021/2022259 12 0 3 12 51 17 7 15 16 8 72 46
2022/2023423 88 63 38 35 65 31 9 32 21 22 15 4
2023/2024356 13 27 21 32 36 60 12 26 1 37 42 49
2024/2025419 213 67 92 47 0 0 0 0 0 0 0 0
Totale 1.580